• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

IDWeek 2024

October 16 – 19 , 2024

  1. Sipavibart (AZD3152)
  2. Evusheld (tixagevimab/cilgavimab)
  3. IVX-A12
  4. Flumist (Influenza Vaccine Live- Intranasal)
  5. Tozorakimab

PDF

A Need for Infection Prevention Among Patients With ESKD on Maintenance Dialysis: A First Step in Understanding How SARS-CoV-2 Impacts This Population

PDF

Individuals on Immunosuppressive or Immunomodulatory Therapies Remain at Increased Risk of COVID-19 Hospitalization, Despite Vaccination: Findings from INFORM, a Retrospective Health Database Study in England

PDF

COVID-19 Mortality Among Immunocompromised Individuals Is Consistently High Compared With Non-Immunocompromised Individuals: Results of the INFORM Study 2022, England

PDF

Safety and Pharmacokinetics of Long-acting SARS-Cov-2 Antibodies Tixagevimab/Cilgavimab (AZD7442) are Consistent After Repeat Dosing: Results From the PROVENT Substudy

PDF

Safety, Immunogenicity, and Pharmacokinetics of Repeat Dosing with AZD7442 (Tixagevimab/Cilgavimab): Final Analysis of the ENDURE Phase 2, Dose-Ranging Study in Immunocompromised Participants

PDF

Safety and Immunogenicity of a Respiratory Syncytial Virus and Human Metapneumovirus Virus-Like Particle Protein Subunit Combination Vaccine in 60 to 85-Year-Old Adults: Interim Results from a Phase 2a Clinical Trial

PDF

Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children: Data From the 2023/24 Influenza Season

PDF

Clinical Outcomes in Adults Hospitalized with Viral Lower Respiratory Tract Disease with a Bacterial and/or Fungal Coinfection: A US Claims Data Base Study

PDF

Temporal Patterns of Hospitalizations and Clinical Outcomes Associated with Viral Lower Respiratory Tract Disease in 2015-2023: A US Claims Analysis

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No